Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS To Test Value-Based Insurance Design; Diabetes, COPD Among Target Diseases

This article was originally published in RPM Report

Executive Summary

The pharmaceutical industry should welcome a test of VBID that will begin in 2017. While it focuses primarily on disease areas with high generic drug usage, it nevertheless can help demonstrate that assuring greater use of pharmaceuticals can be cost effective – offering a nice counter to the relentless focus on drug pricing as a negative.


Related Content

Medicare Value-Based Model May Provide Test For Biosimilars – At Some Point





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts